By Nicole Ireland -CP-A new guideline for treating obesity in children and adolescents says medication can be helpful, but that health providers should prioritize addressing nutrition, exercise and psychological needs. Obesity Canada’s first update to the pediatric obesity management guideline in almost 20 years was published in the Canadian Medical Association Journal this week. The organization’s scientific director, Dr. Sanjeev Sockalingam, says both the scientific understanding and societal impact of obesity have since changed dramatically. Sockalingam says one of the major changes is the development of GLP-1 agonist drugs — such as Ozempic, Wegovy or Mounjaro — for diabetes and weight loss. Wegovy has been studied for weight loss in adolescents 12 years of age and over. Ozempic and Mounjaro have only been approved by Health Canada for treatment of…
Register
